- AMAG Pharmaceuticals (NASDAQ:AMAG) initiated with Overweight rating and $26 (39% upside) price target by Morgan Stanley (NYSE:MS).
- LivaNova (NASDAQ:LIVN) initiated with Buy rating and $76 (20% upside) price target by Jefferies.
- TherapeuticsMD (NYSEMKT:TXMD) initiated with Equal Weight rating and $6 (13% downside risk) price target by Morgan Stanley.
- McKesson (NYSE:MCK) upgraded to Buy by Needham citing stabilization of environment, although generic price deflation still an issue.
- NewLink Genetics (NASDAQ:NLNK) upgraded to Buy with a $26 (91% upside) price target by Jefferies.
- U.S. Physical Therapy (NASDAQ:USPH) upgraded to Buy by Sidoti.
- Fate Therapeutics (NASDAQ:FATE) resumed with Outperform rating and $7 (67% upside) price target by Leerink.
- Axovant Sciences (NYSE:AXON) resumed with Outperform rating and $30 (43% upside) price target by Evercore ISI.
- Catalent (NYSE:CTLT) downgraded to Sector Weight by Keybanc.
- GlaxoSmithKline (NYSE:GSK) downgraded to Underweight by Morgan Stanley.
- Now read: Catalent: A Pricing Agonist Play On Pharmaceuticals
Original article